Phase 1 N=13 Barre Exercise in Parkinson's
Parkinson Disease
Primary: Attendance — 10 Participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=104 Sweet Consumption and Subsequent Sweet Food Preferences and Intakes
Dietary Behaviour
Primary: Sweet Food Preferences — 66; 63; 68 score on a scale
Phase 2 N=141 Study to Assess the Efficacy and Safety of Nivolumab in Combination With Paclitaxel in Subjects With Head and Neck Cancer Unable for Cisplatin-based Chemotherapy (NIVOTAX)
Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma
Primary: Two Years Overall Survival (OS) — 24.7; 13.4 percentage of participants
N/A N=474 Come As You Are - Assessing the Efficacy of a Nurse Case Management HIV Prevention and Care Intervention Among Homeless Youth
Behavior, Risk
Primary: Number of Participants Who Use Preventive Prophylaxis (PrEP) — 20; 18 Participants
N/A N=30 Evaluation of Using Different Screwed Abutment Height
Bone Loss
Primary: Marginal Bone Loss — 1.17; 0.83; 1.28; 0.96 millimeters
N/A N=20 Electrophysiologic Studies of Cognition in Epilepsy Patients
Drug-resistant Epilepsy
Primary: Heartbeat Evoked Potential (HEP) for Attention — -1.5 µV
N/A N=13 Clinical Outcomes With Passive MPKs vs. Powered Prosthetic Knees
Amputation · Amputation; Traumatic, Leg, Lower · Limb; Absence, Congenital, Lower
Primary: Daily Step Count — 5747; 3162 Steps/day
Phase 3 N=66 Phase 3, Sciatic Nerve Block With EXPAREL for Subjects Undergoing Bunionectomy
Bunionectomy · Hallux Valgus
Primary: NRS Pain Scores Through 96 Hours Post-surgery — 342.3; 201.3; 377.4 units on a scale*hours — p=<0.00001
Phase 2 N=82 Study of NGM282 in Patients With Nonalcoholic Steatohepatitis (NASH)
Nonalcoholic Steatohepatitis (NASH)
Primary: Change in Absolute Liver Fat Content (Part 1) — -9.68; -11.91; -0.85 percent of liver fat — p=<0.001
Phase 1 N=51 Study of V117957 in Overactive Bladder Syndrome
Overactive Bladder Syndrome
Primary: Change From Baseline in Micturition Episode Components (Micturition, Incontinence, and Urgency) Per 24 Hours. — -0.8; -0.8; -0.2; -0.4 Episodes per 24 hours
N/A N=536 DeADT - Living Well With Prostate Cancer
Prostate Cancer
Primary: Effectiveness - Interruption in Low Value ADT Injection (i.e., Take a Break From ADT) — 12; 28; 24 Participants
N/A N=14 Enhancing Physical Function in the Long-term for Older Adults
Weight Loss Maintenance
Primary: Proportion Retention — 93 percent of participants
Phase 2 N=70 Ixazomib and Dexamethasone Versus Ixazomib, Dexamethasone and Lenalidomide, Randomized With NFKB2 Rearrangement
Recurrent Plasma Cell Myeloma · Refractory Plasma Cell Myeloma
Primary: The Primary Objective of the Study is to Test Whether the NFKB2 Rearrangement Can Guide the Selection of Treatment (Ixazomib Plus Dexamethasone (Id) or Ixazomib Plus…
N/A N=55 Intermittent Fasting and Metabolic Dysfunction Associated Fatty Liver Disease
Intermittent Fasting · Metabolic Dysfunction-Associated Fatty Liver Disease
Primary: Transient Elastography-Controlled Attenuation Parameter — 319.5; 343.5; 291.5; 285.0 db/m
Phase 1 N=62 MEN1611 With Trastuzumab (+/- Fulvestrant) in Metastatic Breast Cancer
Advanced or Metastatic Breast Cancer
Primary: MTD of MEN1611 in Combination With Trastuzumab ± Fulvestrant — 48 milligrams (mg)